nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—CYP2C18—Ifosfamide—testicular cancer	0.153	0.194	CbGbCtD
Lidocaine—SLC22A5—Dactinomycin—testicular cancer	0.0826	0.105	CbGbCtD
Lidocaine—CYP2A6—Ifosfamide—testicular cancer	0.0742	0.0941	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0507	0.0643	CbGbCtD
Lidocaine—CYP3A7—Ifosfamide—testicular cancer	0.0507	0.0643	CbGbCtD
Lidocaine—CYP2B6—Ifosfamide—testicular cancer	0.0483	0.0612	CbGbCtD
Lidocaine—CYP3A5—Ifosfamide—testicular cancer	0.0381	0.0482	CbGbCtD
Lidocaine—CYP2C8—Ifosfamide—testicular cancer	0.0366	0.0464	CbGbCtD
Lidocaine—CYP2C9—Ifosfamide—testicular cancer	0.0255	0.0323	CbGbCtD
Lidocaine—CYP2B6—Cisplatin—testicular cancer	0.0235	0.0298	CbGbCtD
Lidocaine—ABCB1—Dactinomycin—testicular cancer	0.021	0.0266	CbGbCtD
Lidocaine—CYP3A5—Etoposide—testicular cancer	0.0182	0.0231	CbGbCtD
Lidocaine—CYP2C8—Etoposide—testicular cancer	0.0175	0.0222	CbGbCtD
Lidocaine—CYP2B6—Doxorubicin—testicular cancer	0.0157	0.02	CbGbCtD
Lidocaine—CYP3A4—Ifosfamide—testicular cancer	0.0148	0.0188	CbGbCtD
Lidocaine—CYP1A2—Etoposide—testicular cancer	0.0135	0.0172	CbGbCtD
Lidocaine—ABCB1—Vinblastine—testicular cancer	0.0131	0.0167	CbGbCtD
Lidocaine—CYP2C9—Cisplatin—testicular cancer	0.0124	0.0157	CbGbCtD
Lidocaine—CYP2D6—Vinblastine—testicular cancer	0.0124	0.0157	CbGbCtD
Lidocaine—ABCB1—Cisplatin—testicular cancer	0.012	0.0153	CbGbCtD
Lidocaine—ABCB1—Etoposide—testicular cancer	0.0118	0.015	CbGbCtD
Lidocaine—ABCB1—Doxorubicin—testicular cancer	0.00807	0.0102	CbGbCtD
Lidocaine—CYP3A4—Vinblastine—testicular cancer	0.00787	0.00998	CbGbCtD
Lidocaine—ABCB1—Methotrexate—testicular cancer	0.00782	0.00991	CbGbCtD
Lidocaine—CYP2D6—Doxorubicin—testicular cancer	0.00761	0.00964	CbGbCtD
Lidocaine—CYP3A4—Etoposide—testicular cancer	0.00709	0.00899	CbGbCtD
Lidocaine—CYP3A4—Doxorubicin—testicular cancer	0.00484	0.00613	CbGbCtD
Lidocaine—Eye disorder—Etoposide—testicular cancer	0.000305	0.00147	CcSEcCtD
Lidocaine—Flushing—Etoposide—testicular cancer	0.000303	0.00146	CcSEcCtD
Lidocaine—Cardiac disorder—Etoposide—testicular cancer	0.000303	0.00146	CcSEcCtD
Lidocaine—Hypersensitivity—Vinblastine—testicular cancer	0.0003	0.00144	CcSEcCtD
Lidocaine—Visual disturbance—Methotrexate—testicular cancer	0.000298	0.00144	CcSEcCtD
Lidocaine—Angiopathy—Etoposide—testicular cancer	0.000296	0.00143	CcSEcCtD
Lidocaine—Confusional state—Ifosfamide—testicular cancer	0.000296	0.00143	CcSEcCtD
Lidocaine—Immune system disorder—Etoposide—testicular cancer	0.000295	0.00142	CcSEcCtD
Lidocaine—Pain—Bleomycin—testicular cancer	0.000294	0.00141	CcSEcCtD
Lidocaine—Anaphylactic shock—Ifosfamide—testicular cancer	0.000294	0.00141	CcSEcCtD
Lidocaine—Oedema—Ifosfamide—testicular cancer	0.000294	0.00141	CcSEcCtD
Lidocaine—Chills—Etoposide—testicular cancer	0.000293	0.00141	CcSEcCtD
Lidocaine—Vision blurred—Cisplatin—testicular cancer	0.000292	0.00141	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Methotrexate—testicular cancer	0.000292	0.00141	CcSEcCtD
Lidocaine—Asthenia—Vinblastine—testicular cancer	0.000292	0.00141	CcSEcCtD
Lidocaine—Tremor—Cisplatin—testicular cancer	0.000291	0.0014	CcSEcCtD
Lidocaine—Nervous system disorder—Ifosfamide—testicular cancer	0.000288	0.00139	CcSEcCtD
Lidocaine—Hyperhidrosis—Ifosfamide—testicular cancer	0.000284	0.00137	CcSEcCtD
Lidocaine—Feeling abnormal—Bleomycin—testicular cancer	0.000283	0.00136	CcSEcCtD
Lidocaine—Osteoarthritis—Methotrexate—testicular cancer	0.000283	0.00136	CcSEcCtD
Lidocaine—Vomiting—Chlorambucil—testicular cancer	0.000282	0.00136	CcSEcCtD
Lidocaine—Dysgeusia—Etoposide—testicular cancer	0.000278	0.00134	CcSEcCtD
Lidocaine—Dermatitis bullous—Epirubicin—testicular cancer	0.000277	0.00133	CcSEcCtD
Lidocaine—Back pain—Etoposide—testicular cancer	0.000275	0.00132	CcSEcCtD
Lidocaine—Hypotension—Ifosfamide—testicular cancer	0.000274	0.00132	CcSEcCtD
Lidocaine—Pain—Dactinomycin—testicular cancer	0.000274	0.00132	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Epirubicin—testicular cancer	0.000273	0.00132	CcSEcCtD
Lidocaine—Urticaria—Bleomycin—testicular cancer	0.000273	0.00131	CcSEcCtD
Lidocaine—Dizziness—Vinblastine—testicular cancer	0.000269	0.0013	CcSEcCtD
Lidocaine—Convulsion—Cisplatin—testicular cancer	0.000269	0.00129	CcSEcCtD
Lidocaine—Osteoarthritis—Epirubicin—testicular cancer	0.000264	0.00127	CcSEcCtD
Lidocaine—Diplopia—Epirubicin—testicular cancer	0.000264	0.00127	CcSEcCtD
Lidocaine—Feeling abnormal—Dactinomycin—testicular cancer	0.000264	0.00127	CcSEcCtD
Lidocaine—Nausea—Chlorambucil—testicular cancer	0.000264	0.00127	CcSEcCtD
Lidocaine—Paraesthesia—Ifosfamide—testicular cancer	0.000264	0.00127	CcSEcCtD
Lidocaine—Anxiety—Cisplatin—testicular cancer	0.000263	0.00127	CcSEcCtD
Lidocaine—Dyspnoea—Ifosfamide—testicular cancer	0.000262	0.00126	CcSEcCtD
Lidocaine—Somnolence—Ifosfamide—testicular cancer	0.000261	0.00126	CcSEcCtD
Lidocaine—Vomiting—Vinblastine—testicular cancer	0.000259	0.00125	CcSEcCtD
Lidocaine—Dermatitis bullous—Doxorubicin—testicular cancer	0.000256	0.00123	CcSEcCtD
Lidocaine—Headache—Vinblastine—testicular cancer	0.000255	0.00123	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000253	0.00122	CcSEcCtD
Lidocaine—Anaphylactic shock—Cisplatin—testicular cancer	0.000253	0.00122	CcSEcCtD
Lidocaine—Oedema—Cisplatin—testicular cancer	0.000253	0.00122	CcSEcCtD
Lidocaine—Hypersensitivity—Bleomycin—testicular cancer	0.000253	0.00122	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.000253	0.00122	CcSEcCtD
Lidocaine—Cardiac arrest—Epirubicin—testicular cancer	0.000251	0.00121	CcSEcCtD
Lidocaine—Pain—Ifosfamide—testicular cancer	0.000251	0.00121	CcSEcCtD
Lidocaine—Loss of consciousness—Etoposide—testicular cancer	0.00025	0.0012	CcSEcCtD
Lidocaine—Nervous system disorder—Cisplatin—testicular cancer	0.000248	0.0012	CcSEcCtD
Lidocaine—Asthenia—Bleomycin—testicular cancer	0.000246	0.00119	CcSEcCtD
Lidocaine—Convulsion—Etoposide—testicular cancer	0.000246	0.00119	CcSEcCtD
Lidocaine—Hypertension—Etoposide—testicular cancer	0.000245	0.00118	CcSEcCtD
Lidocaine—Diplopia—Doxorubicin—testicular cancer	0.000245	0.00118	CcSEcCtD
Lidocaine—Osteoarthritis—Doxorubicin—testicular cancer	0.000245	0.00118	CcSEcCtD
Lidocaine—Hyperhidrosis—Cisplatin—testicular cancer	0.000245	0.00118	CcSEcCtD
Lidocaine—Asthma—Methotrexate—testicular cancer	0.000244	0.00118	CcSEcCtD
Lidocaine—Feeling abnormal—Ifosfamide—testicular cancer	0.000242	0.00117	CcSEcCtD
Lidocaine—Chest pain—Etoposide—testicular cancer	0.000242	0.00116	CcSEcCtD
Lidocaine—Nausea—Vinblastine—testicular cancer	0.000242	0.00116	CcSEcCtD
Lidocaine—Hypotension—Cisplatin—testicular cancer	0.000237	0.00114	CcSEcCtD
Lidocaine—Hypersensitivity—Dactinomycin—testicular cancer	0.000236	0.00114	CcSEcCtD
Lidocaine—Confusional state—Etoposide—testicular cancer	0.000234	0.00113	CcSEcCtD
Lidocaine—Urticaria—Ifosfamide—testicular cancer	0.000233	0.00112	CcSEcCtD
Lidocaine—Cardiac arrest—Doxorubicin—testicular cancer	0.000233	0.00112	CcSEcCtD
Lidocaine—Anaphylactic shock—Etoposide—testicular cancer	0.000232	0.00112	CcSEcCtD
Lidocaine—Asthenia—Dactinomycin—testicular cancer	0.00023	0.00111	CcSEcCtD
Lidocaine—Dysphagia—Epirubicin—testicular cancer	0.000229	0.0011	CcSEcCtD
Lidocaine—Asthma—Epirubicin—testicular cancer	0.000229	0.0011	CcSEcCtD
Lidocaine—Paraesthesia—Cisplatin—testicular cancer	0.000227	0.00109	CcSEcCtD
Lidocaine—Dyspnoea—Cisplatin—testicular cancer	0.000226	0.00109	CcSEcCtD
Lidocaine—Hyperhidrosis—Etoposide—testicular cancer	0.000224	0.00108	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000219	0.00105	CcSEcCtD
Lidocaine—Vomiting—Bleomycin—testicular cancer	0.000218	0.00105	CcSEcCtD
Lidocaine—Drowsiness—Methotrexate—testicular cancer	0.000218	0.00105	CcSEcCtD
Lidocaine—Hypotension—Etoposide—testicular cancer	0.000217	0.00104	CcSEcCtD
Lidocaine—Rash—Bleomycin—testicular cancer	0.000217	0.00104	CcSEcCtD
Lidocaine—Pain—Cisplatin—testicular cancer	0.000216	0.00104	CcSEcCtD
Lidocaine—Dermatitis—Bleomycin—testicular cancer	0.000216	0.00104	CcSEcCtD
Lidocaine—Hypersensitivity—Ifosfamide—testicular cancer	0.000216	0.00104	CcSEcCtD
Lidocaine—Stomatitis—Methotrexate—testicular cancer	0.000212	0.00102	CcSEcCtD
Lidocaine—Asthma—Doxorubicin—testicular cancer	0.000211	0.00102	CcSEcCtD
Lidocaine—Dysphagia—Doxorubicin—testicular cancer	0.000211	0.00102	CcSEcCtD
Lidocaine—Asthenia—Ifosfamide—testicular cancer	0.000211	0.00101	CcSEcCtD
Lidocaine—Feeling abnormal—Cisplatin—testicular cancer	0.000209	0.001	CcSEcCtD
Lidocaine—Paraesthesia—Etoposide—testicular cancer	0.000208	0.001	CcSEcCtD
Lidocaine—Dyspnoea—Etoposide—testicular cancer	0.000207	0.000996	CcSEcCtD
Lidocaine—Somnolence—Etoposide—testicular cancer	0.000206	0.000993	CcSEcCtD
Lidocaine—Nausea—Bleomycin—testicular cancer	0.000204	0.000983	CcSEcCtD
Lidocaine—Drowsiness—Epirubicin—testicular cancer	0.000204	0.000982	CcSEcCtD
Lidocaine—Vomiting—Dactinomycin—testicular cancer	0.000204	0.000981	CcSEcCtD
Lidocaine—Rash—Dactinomycin—testicular cancer	0.000202	0.000973	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Etoposide—testicular cancer	0.0002	0.000964	CcSEcCtD
Lidocaine—Neuropathy peripheral—Epirubicin—testicular cancer	0.0002	0.000962	CcSEcCtD
Lidocaine—Stomatitis—Epirubicin—testicular cancer	0.000199	0.000957	CcSEcCtD
Lidocaine—Pain—Etoposide—testicular cancer	0.000198	0.000955	CcSEcCtD
Lidocaine—Haemoglobin—Methotrexate—testicular cancer	0.000196	0.000946	CcSEcCtD
Lidocaine—Haemorrhage—Methotrexate—testicular cancer	0.000195	0.000942	CcSEcCtD
Lidocaine—Dizziness—Ifosfamide—testicular cancer	0.000194	0.000935	CcSEcCtD
Lidocaine—Feeling abnormal—Etoposide—testicular cancer	0.000191	0.00092	CcSEcCtD
Lidocaine—Nausea—Dactinomycin—testicular cancer	0.00019	0.000917	CcSEcCtD
Lidocaine—Drowsiness—Doxorubicin—testicular cancer	0.000189	0.000908	CcSEcCtD
Lidocaine—Visual impairment—Methotrexate—testicular cancer	0.000188	0.000907	CcSEcCtD
Lidocaine—Vomiting—Ifosfamide—testicular cancer	0.000187	0.000899	CcSEcCtD
Lidocaine—Hypersensitivity—Cisplatin—testicular cancer	0.000186	0.000898	CcSEcCtD
Lidocaine—Bradycardia—Epirubicin—testicular cancer	0.000186	0.000897	CcSEcCtD
Lidocaine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000186	0.0536	CbGpPWpGaD
Lidocaine—Rash—Ifosfamide—testicular cancer	0.000185	0.000892	CcSEcCtD
Lidocaine—Dermatitis—Ifosfamide—testicular cancer	0.000185	0.000891	CcSEcCtD
Lidocaine—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000185	0.00089	CcSEcCtD
Lidocaine—Urticaria—Etoposide—testicular cancer	0.000184	0.000887	CcSEcCtD
Lidocaine—Haemoglobin—Epirubicin—testicular cancer	0.000184	0.000886	CcSEcCtD
Lidocaine—Stomatitis—Doxorubicin—testicular cancer	0.000184	0.000885	CcSEcCtD
Lidocaine—Rhinitis—Epirubicin—testicular cancer	0.000183	0.000883	CcSEcCtD
Lidocaine—Haemorrhage—Epirubicin—testicular cancer	0.000183	0.000881	CcSEcCtD
Lidocaine—Eye disorder—Methotrexate—testicular cancer	0.000183	0.00088	CcSEcCtD
Lidocaine—Tinnitus—Methotrexate—testicular cancer	0.000182	0.000878	CcSEcCtD
Lidocaine—Hypoaesthesia—Epirubicin—testicular cancer	0.000182	0.000877	CcSEcCtD
Lidocaine—Asthenia—Cisplatin—testicular cancer	0.000182	0.000875	CcSEcCtD
Lidocaine—Cardiac disorder—Methotrexate—testicular cancer	0.000181	0.000874	CcSEcCtD
Lidocaine—Angiopathy—Methotrexate—testicular cancer	0.000177	0.000854	CcSEcCtD
Lidocaine—Immune system disorder—Methotrexate—testicular cancer	0.000177	0.00085	CcSEcCtD
Lidocaine—Visual impairment—Epirubicin—testicular cancer	0.000176	0.000849	CcSEcCtD
Lidocaine—Chills—Methotrexate—testicular cancer	0.000175	0.000845	CcSEcCtD
Lidocaine—Nausea—Ifosfamide—testicular cancer	0.000174	0.00084	CcSEcCtD
Lidocaine—Bradycardia—Doxorubicin—testicular cancer	0.000172	0.00083	CcSEcCtD
Lidocaine—Eye disorder—Epirubicin—testicular cancer	0.000171	0.000823	CcSEcCtD
Lidocaine—Hypersensitivity—Etoposide—testicular cancer	0.000171	0.000823	CcSEcCtD
Lidocaine—Tinnitus—Epirubicin—testicular cancer	0.000171	0.000822	CcSEcCtD
Lidocaine—Erythema—Methotrexate—testicular cancer	0.00017	0.00082	CcSEcCtD
Lidocaine—Haemoglobin—Doxorubicin—testicular cancer	0.00017	0.000819	CcSEcCtD
Lidocaine—Cardiac disorder—Epirubicin—testicular cancer	0.00017	0.000818	CcSEcCtD
Lidocaine—Flushing—Epirubicin—testicular cancer	0.00017	0.000818	CcSEcCtD
Lidocaine—Rhinitis—Doxorubicin—testicular cancer	0.00017	0.000817	CcSEcCtD
Lidocaine—Haemorrhage—Doxorubicin—testicular cancer	0.000169	0.000815	CcSEcCtD
Lidocaine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000168	0.000811	CcSEcCtD
Lidocaine—Dysgeusia—Methotrexate—testicular cancer	0.000167	0.000803	CcSEcCtD
Lidocaine—Asthenia—Etoposide—testicular cancer	0.000166	0.000801	CcSEcCtD
Lidocaine—Angiopathy—Epirubicin—testicular cancer	0.000166	0.000799	CcSEcCtD
Lidocaine—Immune system disorder—Epirubicin—testicular cancer	0.000165	0.000796	CcSEcCtD
Lidocaine—Back pain—Methotrexate—testicular cancer	0.000165	0.000793	CcSEcCtD
Lidocaine—Chills—Epirubicin—testicular cancer	0.000164	0.000791	CcSEcCtD
Lidocaine—Visual impairment—Doxorubicin—testicular cancer	0.000163	0.000786	CcSEcCtD
Lidocaine—Vomiting—Cisplatin—testicular cancer	0.000161	0.000775	CcSEcCtD
Lidocaine—Vision blurred—Methotrexate—testicular cancer	0.00016	0.000772	CcSEcCtD
Lidocaine—Rash—Cisplatin—testicular cancer	0.00016	0.000769	CcSEcCtD
Lidocaine—Dermatitis—Cisplatin—testicular cancer	0.000159	0.000768	CcSEcCtD
Lidocaine—Erythema—Epirubicin—testicular cancer	0.000159	0.000767	CcSEcCtD
Lidocaine—Eye disorder—Doxorubicin—testicular cancer	0.000158	0.000762	CcSEcCtD
Lidocaine—Tinnitus—Doxorubicin—testicular cancer	0.000158	0.00076	CcSEcCtD
Lidocaine—Cardiac disorder—Doxorubicin—testicular cancer	0.000157	0.000757	CcSEcCtD
Lidocaine—Flushing—Doxorubicin—testicular cancer	0.000157	0.000757	CcSEcCtD
Lidocaine—Tension—Epirubicin—testicular cancer	0.000156	0.000753	CcSEcCtD
Lidocaine—Dysgeusia—Epirubicin—testicular cancer	0.000156	0.000751	CcSEcCtD
Lidocaine—Nervousness—Epirubicin—testicular cancer	0.000155	0.000745	CcSEcCtD
Lidocaine—Back pain—Epirubicin—testicular cancer	0.000154	0.000742	CcSEcCtD
Lidocaine—Angiopathy—Doxorubicin—testicular cancer	0.000154	0.00074	CcSEcCtD
Lidocaine—Dizziness—Etoposide—testicular cancer	0.000153	0.000738	CcSEcCtD
Lidocaine—Immune system disorder—Doxorubicin—testicular cancer	0.000153	0.000736	CcSEcCtD
Lidocaine—Chills—Doxorubicin—testicular cancer	0.000152	0.000732	CcSEcCtD
Lidocaine—Nausea—Cisplatin—testicular cancer	0.00015	0.000724	CcSEcCtD
Lidocaine—Vision blurred—Epirubicin—testicular cancer	0.00015	0.000723	CcSEcCtD
Lidocaine—Convulsion—Methotrexate—testicular cancer	0.000147	0.00071	CcSEcCtD
Lidocaine—Vomiting—Etoposide—testicular cancer	0.000147	0.00071	CcSEcCtD
Lidocaine—Erythema—Doxorubicin—testicular cancer	0.000147	0.00071	CcSEcCtD
Lidocaine—Agitation—Epirubicin—testicular cancer	0.000146	0.000705	CcSEcCtD
Lidocaine—Rash—Etoposide—testicular cancer	0.000146	0.000704	CcSEcCtD
Lidocaine—Dermatitis—Etoposide—testicular cancer	0.000146	0.000703	CcSEcCtD
Lidocaine—Headache—Etoposide—testicular cancer	0.000145	0.0007	CcSEcCtD
Lidocaine—Chest pain—Methotrexate—testicular cancer	0.000145	0.000698	CcSEcCtD
Lidocaine—Tension—Doxorubicin—testicular cancer	0.000145	0.000696	CcSEcCtD
Lidocaine—Dysgeusia—Doxorubicin—testicular cancer	0.000144	0.000695	CcSEcCtD
Lidocaine—Nervousness—Doxorubicin—testicular cancer	0.000143	0.000689	CcSEcCtD
Lidocaine—Back pain—Doxorubicin—testicular cancer	0.000143	0.000686	CcSEcCtD
Lidocaine—Confusional state—Methotrexate—testicular cancer	0.00014	0.000674	CcSEcCtD
Lidocaine—Loss of consciousness—Epirubicin—testicular cancer	0.00014	0.000674	CcSEcCtD
Lidocaine—Anaphylactic shock—Methotrexate—testicular cancer	0.000139	0.000669	CcSEcCtD
Lidocaine—Vision blurred—Doxorubicin—testicular cancer	0.000139	0.000669	CcSEcCtD
Lidocaine—Convulsion—Epirubicin—testicular cancer	0.000138	0.000665	CcSEcCtD
Lidocaine—Nausea—Etoposide—testicular cancer	0.000138	0.000663	CcSEcCtD
Lidocaine—Hypertension—Epirubicin—testicular cancer	0.000137	0.000662	CcSEcCtD
Lidocaine—Nervous system disorder—Methotrexate—testicular cancer	0.000136	0.000656	CcSEcCtD
Lidocaine—Chest pain—Epirubicin—testicular cancer	0.000136	0.000653	CcSEcCtD
Lidocaine—Agitation—Doxorubicin—testicular cancer	0.000135	0.000652	CcSEcCtD
Lidocaine—Anxiety—Epirubicin—testicular cancer	0.000135	0.000651	CcSEcCtD
Lidocaine—Hyperhidrosis—Methotrexate—testicular cancer	0.000134	0.000647	CcSEcCtD
Lidocaine—Confusional state—Epirubicin—testicular cancer	0.000131	0.000631	CcSEcCtD
Lidocaine—Anaphylactic shock—Epirubicin—testicular cancer	0.00013	0.000626	CcSEcCtD
Lidocaine—Oedema—Epirubicin—testicular cancer	0.00013	0.000626	CcSEcCtD
Lidocaine—Hypotension—Methotrexate—testicular cancer	0.00013	0.000625	CcSEcCtD
Lidocaine—Loss of consciousness—Doxorubicin—testicular cancer	0.00013	0.000624	CcSEcCtD
Lidocaine—Shock—Epirubicin—testicular cancer	0.000128	0.000616	CcSEcCtD
Lidocaine—Convulsion—Doxorubicin—testicular cancer	0.000128	0.000615	CcSEcCtD
Lidocaine—Nervous system disorder—Epirubicin—testicular cancer	0.000127	0.000614	CcSEcCtD
Lidocaine—Hypertension—Doxorubicin—testicular cancer	0.000127	0.000613	CcSEcCtD
Lidocaine—Hyperhidrosis—Epirubicin—testicular cancer	0.000126	0.000605	CcSEcCtD
Lidocaine—Chest pain—Doxorubicin—testicular cancer	0.000125	0.000604	CcSEcCtD
Lidocaine—Anxiety—Doxorubicin—testicular cancer	0.000125	0.000602	CcSEcCtD
Lidocaine—Paraesthesia—Methotrexate—testicular cancer	0.000125	0.000601	CcSEcCtD
Lidocaine—Dyspnoea—Methotrexate—testicular cancer	0.000124	0.000596	CcSEcCtD
Lidocaine—Somnolence—Methotrexate—testicular cancer	0.000123	0.000595	CcSEcCtD
Lidocaine—Hypotension—Epirubicin—testicular cancer	0.000121	0.000585	CcSEcCtD
Lidocaine—Confusional state—Doxorubicin—testicular cancer	0.000121	0.000584	CcSEcCtD
Lidocaine—Anaphylactic shock—Doxorubicin—testicular cancer	0.00012	0.000579	CcSEcCtD
Lidocaine—Oedema—Doxorubicin—testicular cancer	0.00012	0.000579	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00012	0.000577	CcSEcCtD
Lidocaine—Pain—Methotrexate—testicular cancer	0.000119	0.000572	CcSEcCtD
Lidocaine—Shock—Doxorubicin—testicular cancer	0.000118	0.00057	CcSEcCtD
Lidocaine—Nervous system disorder—Doxorubicin—testicular cancer	0.000118	0.000568	CcSEcCtD
Lidocaine—Paraesthesia—Epirubicin—testicular cancer	0.000117	0.000562	CcSEcCtD
Lidocaine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000116	0.00056	CcSEcCtD
Lidocaine—Dyspnoea—Epirubicin—testicular cancer	0.000116	0.000558	CcSEcCtD
Lidocaine—Somnolence—Epirubicin—testicular cancer	0.000116	0.000557	CcSEcCtD
Lidocaine—Feeling abnormal—Methotrexate—testicular cancer	0.000114	0.000551	CcSEcCtD
Lidocaine—Hypotension—Doxorubicin—testicular cancer	0.000112	0.000541	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000112	0.00054	CcSEcCtD
Lidocaine—Pain—Epirubicin—testicular cancer	0.000111	0.000535	CcSEcCtD
Lidocaine—Urticaria—Methotrexate—testicular cancer	0.00011	0.000531	CcSEcCtD
Lidocaine—Paraesthesia—Doxorubicin—testicular cancer	0.000108	0.00052	CcSEcCtD
Lidocaine—Dyspnoea—Doxorubicin—testicular cancer	0.000107	0.000516	CcSEcCtD
Lidocaine—Feeling abnormal—Epirubicin—testicular cancer	0.000107	0.000516	CcSEcCtD
Lidocaine—Somnolence—Doxorubicin—testicular cancer	0.000107	0.000515	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000104	0.0005	CcSEcCtD
Lidocaine—SCN9A—Developmental Biology—PRDM14—testicular cancer	0.000104	0.0299	CbGpPWpGaD
Lidocaine—Urticaria—Epirubicin—testicular cancer	0.000103	0.000497	CcSEcCtD
Lidocaine—Pain—Doxorubicin—testicular cancer	0.000103	0.000495	CcSEcCtD
Lidocaine—Hypersensitivity—Methotrexate—testicular cancer	0.000102	0.000493	CcSEcCtD
Lidocaine—Asthenia—Methotrexate—testicular cancer	9.96e-05	0.00048	CcSEcCtD
Lidocaine—Feeling abnormal—Doxorubicin—testicular cancer	9.91e-05	0.000477	CcSEcCtD
Lidocaine—SCN3A—Developmental Biology—PRDM14—testicular cancer	9.9e-05	0.0286	CbGpPWpGaD
Lidocaine—Hypersensitivity—Epirubicin—testicular cancer	9.58e-05	0.000461	CcSEcCtD
Lidocaine—Urticaria—Doxorubicin—testicular cancer	9.55e-05	0.00046	CcSEcCtD
Lidocaine—SCN4A—Developmental Biology—PRDM14—testicular cancer	9.51e-05	0.0274	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—PRDM14—testicular cancer	9.51e-05	0.0274	CbGpPWpGaD
Lidocaine—Asthenia—Epirubicin—testicular cancer	9.33e-05	0.000449	CcSEcCtD
Lidocaine—Dizziness—Methotrexate—testicular cancer	9.18e-05	0.000442	CcSEcCtD
Lidocaine—SCN10A—Developmental Biology—PRDM14—testicular cancer	9.17e-05	0.0265	CbGpPWpGaD
Lidocaine—Hypersensitivity—Doxorubicin—testicular cancer	8.86e-05	0.000427	CcSEcCtD
Lidocaine—Vomiting—Methotrexate—testicular cancer	8.83e-05	0.000425	CcSEcCtD
Lidocaine—Rash—Methotrexate—testicular cancer	8.76e-05	0.000422	CcSEcCtD
Lidocaine—Dermatitis—Methotrexate—testicular cancer	8.75e-05	0.000421	CcSEcCtD
Lidocaine—Headache—Methotrexate—testicular cancer	8.7e-05	0.000419	CcSEcCtD
Lidocaine—Asthenia—Doxorubicin—testicular cancer	8.63e-05	0.000416	CcSEcCtD
Lidocaine—Dizziness—Epirubicin—testicular cancer	8.6e-05	0.000414	CcSEcCtD
Lidocaine—SLC22A5—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	8.45e-05	0.0244	CbGpPWpGaD
Lidocaine—EGFR—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	8.35e-05	0.0241	CbGpPWpGaD
Lidocaine—Vomiting—Epirubicin—testicular cancer	8.26e-05	0.000398	CcSEcCtD
Lidocaine—Nausea—Methotrexate—testicular cancer	8.25e-05	0.000397	CcSEcCtD
Lidocaine—Rash—Epirubicin—testicular cancer	8.2e-05	0.000395	CcSEcCtD
Lidocaine—Dermatitis—Epirubicin—testicular cancer	8.19e-05	0.000394	CcSEcCtD
Lidocaine—Headache—Epirubicin—testicular cancer	8.14e-05	0.000392	CcSEcCtD
Lidocaine—Dizziness—Doxorubicin—testicular cancer	7.95e-05	0.000383	CcSEcCtD
Lidocaine—EGFR—Syndecan-3-mediated signaling events—FGFR3—testicular cancer	7.81e-05	0.0225	CbGpPWpGaD
Lidocaine—CYP2A6—NRF2 pathway—SLC2A6—testicular cancer	7.74e-05	0.0223	CbGpPWpGaD
Lidocaine—Nausea—Epirubicin—testicular cancer	7.72e-05	0.000372	CcSEcCtD
Lidocaine—Vomiting—Doxorubicin—testicular cancer	7.65e-05	0.000368	CcSEcCtD
Lidocaine—Rash—Doxorubicin—testicular cancer	7.58e-05	0.000365	CcSEcCtD
Lidocaine—Dermatitis—Doxorubicin—testicular cancer	7.58e-05	0.000365	CcSEcCtD
Lidocaine—Headache—Doxorubicin—testicular cancer	7.53e-05	0.000363	CcSEcCtD
Lidocaine—Nausea—Doxorubicin—testicular cancer	7.14e-05	0.000344	CcSEcCtD
Lidocaine—SCN5A—Developmental Biology—PRDM14—testicular cancer	6.45e-05	0.0186	CbGpPWpGaD
Lidocaine—EGFR—Bladder Cancer—FGFR3—testicular cancer	5.72e-05	0.0165	CbGpPWpGaD
Lidocaine—SCN5A—Cardiac Progenitor Differentiation—KIT—testicular cancer	5.22e-05	0.0151	CbGpPWpGaD
Lidocaine—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	4.52e-05	0.013	CbGpPWpGaD
Lidocaine—SLC22A5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	4.29e-05	0.0124	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—PRDM14—testicular cancer	4.22e-05	0.0122	CbGpPWpGaD
Lidocaine—CYP2C18—Biological oxidations—HPGDS—testicular cancer	4.04e-05	0.0117	CbGpPWpGaD
Lidocaine—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	3.68e-05	0.0106	CbGpPWpGaD
Lidocaine—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	3.4e-05	0.00981	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	3.36e-05	0.0097	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	3.32e-05	0.00956	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	3.17e-05	0.00913	CbGpPWpGaD
Lidocaine—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	3.15e-05	0.00907	CbGpPWpGaD
Lidocaine—EGFR—PI-3K cascade—KITLG—testicular cancer	3.06e-05	0.00883	CbGpPWpGaD
Lidocaine—EGFR—PI3K/AKT activation—KITLG—testicular cancer	2.99e-05	0.00862	CbGpPWpGaD
Lidocaine—EGFR—GAB1 signalosome—KITLG—testicular cancer	2.97e-05	0.00856	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—BCL10—testicular cancer	2.93e-05	0.00845	CbGpPWpGaD
Lidocaine—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	2.9e-05	0.00836	CbGpPWpGaD
Lidocaine—CYP3A7—Biological oxidations—HPGDS—testicular cancer	2.69e-05	0.00775	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.67e-05	0.0077	CbGpPWpGaD
Lidocaine—EGFR—LPA receptor mediated events—MMP2—testicular cancer	2.61e-05	0.00751	CbGpPWpGaD
Lidocaine—EGFR—AGE/RAGE pathway—MMP2—testicular cancer	2.54e-05	0.00733	CbGpPWpGaD
Lidocaine—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	2.53e-05	0.00729	CbGpPWpGaD
Lidocaine—CYP2A6—Biological oxidations—HPGDS—testicular cancer	2.46e-05	0.00711	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—STK11—testicular cancer	2.34e-05	0.00676	CbGpPWpGaD
Lidocaine—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	2.32e-05	0.00669	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—KITLG—testicular cancer	2.29e-05	0.0066	CbGpPWpGaD
Lidocaine—EGFR—PI-3K cascade—FGFR3—testicular cancer	2.28e-05	0.00657	CbGpPWpGaD
Lidocaine—EGFR—PI3K/AKT activation—FGFR3—testicular cancer	2.22e-05	0.00641	CbGpPWpGaD
Lidocaine—EGFR—GAB1 signalosome—FGFR3—testicular cancer	2.21e-05	0.00636	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—KITLG—testicular cancer	2.19e-05	0.00632	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—KITLG—testicular cancer	2.16e-05	0.00622	CbGpPWpGaD
Lidocaine—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	2.16e-05	0.00621	CbGpPWpGaD
Lidocaine—EGFR—PI-3K cascade—KIT—testicular cancer	2.09e-05	0.00603	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—KITLG—testicular cancer	2.06e-05	0.00594	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—KITLG—testicular cancer	2.05e-05	0.00591	CbGpPWpGaD
Lidocaine—EGFR—PI3K/AKT activation—KIT—testicular cancer	2.04e-05	0.00588	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—KITLG—testicular cancer	2.04e-05	0.00588	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—KITLG—testicular cancer	2.03e-05	0.00585	CbGpPWpGaD
Lidocaine—EGFR—GAB1 signalosome—KIT—testicular cancer	2.02e-05	0.00584	CbGpPWpGaD
Lidocaine—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	2e-05	0.00577	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	2e-05	0.00577	CbGpPWpGaD
Lidocaine—CYP2B6—Biological oxidations—HPGDS—testicular cancer	1.99e-05	0.00573	CbGpPWpGaD
Lidocaine—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	1.98e-05	0.0057	CbGpPWpGaD
Lidocaine—CYP3A5—Biological oxidations—HPGDS—testicular cancer	1.94e-05	0.0056	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.94e-05	0.0056	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	1.91e-05	0.0055	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—KITLG—testicular cancer	1.91e-05	0.0055	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—KITLG—testicular cancer	1.91e-05	0.0055	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—KITLG—testicular cancer	1.89e-05	0.00546	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—KITLG—testicular cancer	1.88e-05	0.00541	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—KITLG—testicular cancer	1.87e-05	0.00538	CbGpPWpGaD
Lidocaine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	1.84e-05	0.0053	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—KITLG—testicular cancer	1.77e-05	0.00509	CbGpPWpGaD
Lidocaine—SCN9A—Axon guidance—MMP2—testicular cancer	1.75e-05	0.00503	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—FGFR3—testicular cancer	1.7e-05	0.00491	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	1.69e-05	0.00488	CbGpPWpGaD
Lidocaine—CYP2C8—Biological oxidations—HPGDS—testicular cancer	1.68e-05	0.00485	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—MMP2—testicular cancer	1.67e-05	0.00481	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	1.63e-05	0.0047	CbGpPWpGaD
Lidocaine—EGFR—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	1.63e-05	0.0047	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—INSL3—testicular cancer	1.61e-05	0.00463	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—MMP2—testicular cancer	1.6e-05	0.00462	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—MMP2—testicular cancer	1.6e-05	0.00462	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—FGFR3—testicular cancer	1.6e-05	0.00462	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—KIT—testicular cancer	1.56e-05	0.00451	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—MMP2—testicular cancer	1.55e-05	0.00446	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—FGFR3—testicular cancer	1.53e-05	0.00441	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—FGFR3—testicular cancer	1.52e-05	0.00439	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—FGFR3—testicular cancer	1.52e-05	0.00437	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—FGFR3—testicular cancer	1.51e-05	0.00435	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—KIT—testicular cancer	1.5e-05	0.00431	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	1.49e-05	0.00429	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.48e-05	0.00425	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—KIT—testicular cancer	1.47e-05	0.00424	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—FGFR3—testicular cancer	1.42e-05	0.00409	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—FGFR3—testicular cancer	1.42e-05	0.00409	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	1.42e-05	0.00409	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—FGFR3—testicular cancer	1.41e-05	0.00405	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—KIT—testicular cancer	1.41e-05	0.00405	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—KIT—testicular cancer	1.4e-05	0.00403	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	1.39e-05	0.00402	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—MMP2—testicular cancer	1.39e-05	0.00402	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—KIT—testicular cancer	1.39e-05	0.00401	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—FGFR3—testicular cancer	1.39e-05	0.004	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—KIT—testicular cancer	1.38e-05	0.00399	CbGpPWpGaD
Lidocaine—CYP2D6—Biological oxidations—HPGDS—testicular cancer	1.38e-05	0.00398	CbGpPWpGaD
Lidocaine—CYP2C9—Biological oxidations—HPGDS—testicular cancer	1.37e-05	0.00395	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	1.36e-05	0.00394	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.35e-05	0.00389	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—FGFR3—testicular cancer	1.31e-05	0.00379	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—KIT—testicular cancer	1.3e-05	0.00376	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—KIT—testicular cancer	1.3e-05	0.00376	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	1.3e-05	0.00376	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—KITLG—testicular cancer	1.3e-05	0.00375	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—KIT—testicular cancer	1.29e-05	0.00372	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—KIT—testicular cancer	1.28e-05	0.00369	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—KIT—testicular cancer	1.27e-05	0.00367	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	1.26e-05	0.00362	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—MMP2—testicular cancer	1.25e-05	0.00359	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—BCL10—testicular cancer	1.23e-05	0.00355	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—KIT—testicular cancer	1.21e-05	0.00348	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—MMP2—testicular cancer	1.19e-05	0.00343	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—BCL10—testicular cancer	1.18e-05	0.00341	CbGpPWpGaD
Lidocaine—CYP1A2—Biological oxidations—HPGDS—testicular cancer	1.17e-05	0.00338	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	1.15e-05	0.00333	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—MMP2—testicular cancer	1.14e-05	0.0033	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—MMP2—testicular cancer	1.14e-05	0.0033	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—MMP2—testicular cancer	1.1e-05	0.00318	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—MMP2—testicular cancer	1.09e-05	0.00313	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	9.8e-06	0.00283	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—FGFR3—testicular cancer	9.67e-06	0.00279	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—INSL3—testicular cancer	9.49e-06	0.00274	CbGpPWpGaD
Lidocaine—CYP3A4—Biological oxidations—HPGDS—testicular cancer	9.04e-06	0.00261	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—KIT—testicular cancer	8.88e-06	0.00256	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—MMP2—testicular cancer	7.76e-06	0.00224	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KITLG—testicular cancer	7.42e-06	0.00214	CbGpPWpGaD
Lidocaine—EGFR—Immune System—BCL10—testicular cancer	7.17e-06	0.00207	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KITLG—testicular cancer	7.12e-06	0.00205	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—MMP2—testicular cancer	7.12e-06	0.00205	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—HPGDS—testicular cancer	6.92e-06	0.00199	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.47e-06	0.00186	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—FGFR3—testicular cancer	5.51e-06	0.00159	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—FGFR3—testicular cancer	5.29e-06	0.00153	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.26e-06	0.00152	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MMP2—testicular cancer	5.08e-06	0.00146	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KIT—testicular cancer	5.06e-06	0.00146	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—STK11—testicular cancer	5.03e-06	0.00145	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KIT—testicular cancer	4.86e-06	0.0014	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—HPGDS—testicular cancer	4.6e-06	0.00133	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.5e-06	0.0013	CbGpPWpGaD
Lidocaine—EGFR—Disease—H2AFZ—testicular cancer	4.34e-06	0.00125	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KITLG—testicular cancer	4.32e-06	0.00125	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—HPGDS—testicular cancer	4.22e-06	0.00122	CbGpPWpGaD
Lidocaine—EGFR—Disease—KITLG—testicular cancer	3.99e-06	0.00115	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—HPGDS—testicular cancer	3.4e-06	0.000981	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—STK11—testicular cancer	3.34e-06	0.000963	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—HPGDS—testicular cancer	3.32e-06	0.000958	CbGpPWpGaD
Lidocaine—EGFR—Immune System—FGFR3—testicular cancer	3.21e-06	0.000926	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—STK11—testicular cancer	3.06e-06	0.000883	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—H2AFZ—testicular cancer	3.04e-06	0.000876	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STK11—testicular cancer	3.02e-06	0.00087	CbGpPWpGaD
Lidocaine—EGFR—Disease—FGFR3—testicular cancer	2.97e-06	0.000855	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KIT—testicular cancer	2.95e-06	0.00085	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—HPGDS—testicular cancer	2.88e-06	0.00083	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KITLG—testicular cancer	2.79e-06	0.000805	CbGpPWpGaD
Lidocaine—EGFR—Disease—KIT—testicular cancer	2.72e-06	0.000785	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—HPGDS—testicular cancer	2.51e-06	0.000723	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—STK11—testicular cancer	2.47e-06	0.000712	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—STK11—testicular cancer	2.42e-06	0.000696	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—HPGDS—testicular cancer	2.36e-06	0.000681	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—HPGDS—testicular cancer	2.34e-06	0.000676	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—STK11—testicular cancer	2.09e-06	0.000603	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FGFR3—testicular cancer	2.08e-06	0.000599	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—HPGDS—testicular cancer	2e-06	0.000577	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KIT—testicular cancer	1.91e-06	0.00055	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—STK11—testicular cancer	1.82e-06	0.000525	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—STK11—testicular cancer	1.72e-06	0.000495	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—STK11—testicular cancer	1.7e-06	0.000491	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—HPGDS—testicular cancer	1.55e-06	0.000446	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—STK11—testicular cancer	1.45e-06	0.000419	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—STK11—testicular cancer	1.12e-06	0.000324	CbGpPWpGaD
